Nuclear Osteopontin Is a Marker of Advanced Heart Failure and Cardiac Allograft Vasculopathy: Evidence From Transplant and Retransplant Hearts

Camila Iansen Irion, Julian C. Dunkley, Krista John-Williams, José Manuel Condor Capcha, Serene A. Shehadeh, Andre Pinto, Matthias Loebe, Keith A. Webster, Nicolas A. Brozzi, Lina A. Shehadeh

Research output: Contribution to journalArticle

Abstract

Background: Heart transplant is the gold standard therapy for patients with advanced heart failure. Over 5,500 heart transplants are performed every year worldwide. Cardiac allograft vasculopathy (CAV) is a common complication post-heart transplant which reduces survival and often necessitates heart retransplantation. Post-transplant follow-up requires serial coronary angiography and endomyocardial biopsy (EMB) for CAV and allograft rejection screening, respectively; both of which are invasive procedures. This study aims to determine whether osteopontin (OPN) protein, a fibrosis marker often present in chronic heart disease, represents a novel biomarker for CAV. Methods: Expression of OPN was analyzed in cardiac tissue obtained from patients undergoing heart retransplantation using immunofluorescence imaging (n = 20). Tissues from native explanted hearts and three serial follow-up EMB samples of transplanted hearts were also analyzed in five of these patients. Results: Fifteen out of 20 patients undergoing retransplantation had CAV. 13/15 patients with CAV expressed nuclear OPN. 5/5 patients with multiple tissue samples expressed nuclear OPN in both 1st and 2nd explanted hearts, while 0/5 expressed nuclear OPN in any of the follow-up EMBs. 4/5 of these patients had an initial diagnosis of dilated cardiomyopathy (DCM). Conclusion: Nuclear localization of OPN in cardiomyocytes of patients with CAV was evident at the time of cardiac retransplant as well as in patients with DCM at the time of the 1st transplant. The results implicate nuclear OPN as a novel biomarker for severe CAV and DCM.

Original languageEnglish (US)
Article number928
JournalFrontiers in Physiology
Volume11
DOIs
StatePublished - Aug 13 2020

Keywords

  • cardiac allograft vasculopathy
  • dilated cardiomyopathy
  • endomyocardial biopsy
  • heart retransplantation
  • heart transplant
  • osteopontin

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Nuclear Osteopontin Is a Marker of Advanced Heart Failure and Cardiac Allograft Vasculopathy: Evidence From Transplant and Retransplant Hearts'. Together they form a unique fingerprint.

  • Cite this

    Irion, C. I., Dunkley, J. C., John-Williams, K., Condor Capcha, J. M., Shehadeh, S. A., Pinto, A., Loebe, M., Webster, K. A., Brozzi, N. A., & Shehadeh, L. A. (2020). Nuclear Osteopontin Is a Marker of Advanced Heart Failure and Cardiac Allograft Vasculopathy: Evidence From Transplant and Retransplant Hearts. Frontiers in Physiology, 11, [928]. https://doi.org/10.3389/fphys.2020.00928